Zobrazeno 1 - 10
of 66
pro vyhledávání: '"John H. Rodman"'
Autor:
John H. Rodman, Raymond C. Barfield, John C. Panetta, Wing Leung, Renee Madden, Kimberly A. Kasow, Gregory A. Hale, Paul Woodard, Sandra K. Call, Sharyn D. Baker, Rupert Handgretinger, Edwin M. Horwitz
Publikováno v:
Biology of Blood and Marrow Transplantation. 15(2):274-278
Rabbit antithymocyte globulin (rATG; Thymoglobulin®) is currently used to prevent or treat graft-versus-host disease (GVHD) during hematopoietic stem cell transplantation (HSCT). The dose and schedule of rATG as part of the preparative regimen for u
Autor:
John H. Rodman, Leslie Serchuck, Jose F. Rodriguez, Jane C. Lindsey, Barbara Heckman, Katherine M. Knapp, Jaime Martinez, Patricia M. Flynn, Brian L. Robbins, James McNamara, Edmund V. Capparelli
Publikováno v:
Antimicrobial Agents and Chemotherapy. 51:3516-3522
Zidovudine (ZDV) and lamivudine (3TC) metabolism to triphosphates (TP) is necessary for antiviral activity. The aims of this study were to compare ZDV-TP and 3TC-TP concentrations in adolescents receiving twice daily (BID) and once daily (QD) regimen
Autor:
Leslie Serchuck, Michael Hughes, John H. Rodman, Ruth Dickover, Mobeen H. Rathore, Coleen K. Cunningham, Joyce Kraimer, Adriana Weinberg, Linda Draper, Gregory E. Chittick, M. Robert Blum, Mary E. Smith, Patricia M. Flynn, Stephen A. Spector, Ram Yogev, Ross E. McKinney, Alberto A. Ortiz, Melissa Scites, Elaine J. Abrams, Chengcheng Hu, Paul Tran, Paula Britto, Laurie Reynolds
Publikováno v:
Pediatrics. 120:e416-e423
BACKGROUND. Compliance with complex antiretroviral therapy regimens is a problem for HIV-1–infected children and their families. Simple, safe, and effective regimens are important for long-term therapeutic success. METHODS. A novel, once-daily dosi
Publikováno v:
Journal of Chromatography B. 850:310-317
All nucleoside reverse transcriptase inhibitors (NRTI) must first be metabolized to their triphosphate forms in order to be active against HIV. Zidovudine (ZDV), abacavir (ABC) and lamivudine (3TC) have proven to be an efficacious combination. In ord
Autor:
John H. Rodman, Ram Yogev, Michael Hughes, Christine A. Powell, Katherine Luzuriaga, Paul Palumbo, Ellen G. Chadwick, Paula Britto, Elaine J. Abrams, William Borkowsky, Patricia M. Flynn
Publikováno v:
The Pediatric Infectious Disease Journal. 24:793-800
Few data are available regarding clinical outcomes or dosing requirements for the protease inhibitor ritonavir in human immunodeficiency virus (HIV)-infected children younger than under 24 months of age.This prospective, multicenter phase I/II open l
Publikováno v:
Pharmacotherapy. 23:695-701
Objective As tenofovir disoproxil fumarate substantially increases plasma concentrations of didanosine in patients with human immunodeficiency virus-1 infection, we sought to determine whether tenofovir and didanosine showed a similar intracellular i
Autor:
John H. Rodman, Mary Culnane, Rodney E. Willoughby, Suzette Blanchard, Kenneth C. Cundy, Arnold Fridland, Sandra K. Burchett, Dion F. Coakley, Walter T. Hughes, Jerry L. Shenep, Lynette Purdue, Jennifer S. Read, Bonnie Zimmer
Publikováno v:
Antimicrobial Agents and Chemotherapy. 44:1041-1046
The acyclic phosphonate analog adefovir is a potent inhibitor of retroviruses, including human immunodeficiency virus (HIV) type 1, and, unlike some antiviral nucleosides, does not require the initial phosphorylation step for its activity. Two oral d
Autor:
Vincent J. Carey, Catherine A. Knupp, Lisa M. Frenkel, Florence H. Yong, Robert C. Stevens, John H. Rodman
Publikováno v:
AIDS Research and Human Retroviruses. 16:415-421
The effect of food on didanosine bioavailability and interpatient pharmacokinetic variability was examined in children infected with human immunodeficiency virus type 1 (HIV-1). Didanosine pharmacokinetics were determined during fasting and fed condi
Autor:
John H. Rodman, Richard L. Heideman, William P. Petros, Daryl J. Murry, Margaret E. Tonda, Henry S. Friedman
Publikováno v:
Cancer Chemotherapy and Pharmacology. 38:395-400
Purpose: The pharmacokinetic parameters and maximal tolerated systemic exposure were determined for carboplatin in young children given in combination with cyclophosphamide and etoposide. Patients and methods: Carboplatin was administered as part of
Autor:
John H. Rodman
Publikováno v:
Journal of Adolescent Health. 15:654-662
Although there are convincing clinical studies demonstrating important pharmacokinetic differences between the adult and Pediatric patient, guidelines for adjusting the dosages of specific drugs are often based on empirical and limited data. Adult do